SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief ExecutiveOfficer, will present at the 2005 UBS Global Life Sciences Conference onTuesday, September 27, 2005, at 10:00 a.m. Eastern Time at the Grand HyattNew York in New York City.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com, under the investors section and anarchived recording will be available on the website through October 11, 2005.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of novel treatmentsfor central nervous system disorders. ACADIA currently has four drug programsin clinical development as well as a portfolio of preclinical and discoveryassets directed at large unmet medical needs, including schizophrenia,Parkinson's disease, neuropathic pain, and glaucoma. Using its proprietarydrug discovery platform, ACADIA has discovered all of the drug candidates inits product pipeline. ACADIA's corporate headquarters is located in SanDiego, California, and it maintains research and development operations inboth San Diego and Malmo, Sweden.
CONTACT:
Lisa Barthelemy, Director, Investor Relations, or Thomas H.Aasen, Vice President and Chief Financial Officer, both of ACADIAPharmaceuticals Inc., +1-858-558-2871
Web site: http://www.acadia-pharm.com(ACAD)